drugset
drugset / Trial / NCT03288454

Phase 2 Study of Apixaban Reversal by Ciraparantag as Measured by WBCT

NCT03288454 ↗

Phase 2 Completed 60 enrolled AMAG Pharmaceuticals, Inc.
RandomizedSequentialSingle-blindTreatment

Summary

This study is a randomized, single-blind, placebo-controlled study to assess the efficacy and safety of ciraparantag administered to healthy volunteers anticoagulated with apixaban measuring clotting times using Whole Blood Clotting Time (WBCT).

Timeline

Start
2017-08-30
Primary completion
2019-08-05
Completion
2019-08-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Ciraparantag Small molecule 30 mg Intravenous
Subject Ciraparantag Small molecule 60 mg Intravenous
Subject Ciraparantag Small molecule 120 mg Intravenous
Background Apixaban Small molecule 10 mg Oral

Indications

No indication recorded.